Search

Author/Creator Wiesener, M.

3. Monitoring of complement activation biomarkers and eculizumab in complement‐mediated renal disorders. (25th November 2016)

Authors:
Wehling, C.; Amon, O.; Bommer, M.; Hoppe, B.; Kentouche, K.; Schalk, G.; Weimer, R.; Wiesener, M.; Hohenstein, B.; Tönshoff, B.; Büscher, R.; Fehrenbach, H.; Gök, Ö.‐N.; Kirschfink, M.
Journal:
Clinical and experimental immunology
Issue:
Volume 187:Number 2(2017:Feb.)
Page Start:
304
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. SAT0203 Successful treatment of refractory SLE patients with the proteasome inhibitor bortezomib – a case series. (23rd January 2014)

Authors:
Voll, R.E.; Alexander, T.; Peukert, R.; Rubbert, A.; Rech, J.; Braun, T.; Wiesener, M.; Eckardt, K.-U.; Hoyer, B.; Taddeo, A.; Reisch, A.; Burmester, G.-R.; Radbruch, A.; Schett, G.; Hiepe, F.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71(2012)Supplement 3
Page Start:
540
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗